Literature DB >> 30864902

Low Lymphocyte-to-Monocyte Ratios Are Associated with Poor Overall Survival in Anaplastic Thyroid Carcinoma Patients.

Jonghwa Ahn1, Eyun Song1, Hye-Seon Oh1, Dong Eun Song2, Won Gu Kim1, Tae Yong Kim1, Won Bae Kim1, Young Kee Shong1, Min Ji Jeon1.   

Abstract

Background: The lymphocyte-to-monocyte ratio (LMR), which reflects the tumor-infiltrating immune cell status and host immunity, has been reported as a prognostic marker in various cancers. The aim of the present study was to evaluate the role of the LMR as a prognostic marker in predicting the survival of patients with anaplastic thyroid carcinoma (ATC).
Methods: This study retrospectively included 35 ATC patients with available complete blood cell count data. The primary outcome was the overall survival (OS) of patients with ATC.
Results: There were no significant differences between the LMR of the baseline and that of the follow-up complete blood cell count data (p = 0.53). The patients were divided into two groups based on their baseline LMR: a low LMR group (<4; n = 23, 66%) and a high LMR group (≥4; n = 12, 34%). The proportion of cervical lymph node metastasis in the low LMR group was significantly higher than that in the high LMR group (p = 0.021). The OS curves were significantly different based on the LMR values, and the median OS of the low and high LMR groups were 3.0 and 9.5 months, respectively (p = 0.004). In multivariate analysis, a low LMR was also an independent risk factor for all-cause mortality in patients with ATC (hazard ratio = 2.55 [confidence interval 1.08-6.00], p = 0.032) after adjusting for sex, tumor size, and distant metastasis. Conclusions: A low LMR is associated with poor survival in patients with ATC. The LMR could be a simple and stable prognostic biomarker reflecting host immunity in patients with ATC. Further studies are needed to confirm the prognostic role of the LMR in ATC.

Entities:  

Keywords:  anaplastic thyroid carcinoma; immune system; lymphocytes; monocytes

Mesh:

Year:  2019        PMID: 30864902     DOI: 10.1089/thy.2018.0684

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  16 in total

1.  Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy.

Authors:  Shogo Nakamoto; Masahiko Ikeda; Shinichiro Kubo; Mari Yamamoto; Tetsumasa Yamashita; Chihiro Kuwahara
Journal:  Cancer Diagn Progn       Date:  2021-11-03

2.  Usefulness of pre-thyroidectomy neutrophil-lymphocyte, platelet-lymphocyte, and monocyte-lymphocyte ratios for discriminating lymph node and distant metastases in differentiated thyroid cancer.

Authors:  Cínthia Minatel Riguetto; Icléia Siqueira Barreto; Frederico Fernandes Ribeiro Maia; Lígia Vera Montali da Assumpção; Denise Engelbrecht Zantut-Wittmann
Journal:  Clinics (Sao Paulo)       Date:  2021-08-16       Impact factor: 2.365

3.  Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma.

Authors:  Katrin Rabold; Martijn Zoodsma; Inge Grondman; Yunus Kuijpers; Manita Bremmers; Martin Jaeger; Bowen Zhang; Willemijn Hobo; Han J Bonenkamp; Johannes H W de Wilt; Marcel J R Janssen; Lenneke A M Cornelissen; Ilse C H van Engen-van Grunsven; Willem J M Mulder; Jan W A Smit; Gosse J Adema; Mihai G Netea; Yang Li; Cheng-Jian Xu; Romana T Netea-Maier
Journal:  Nat Commun       Date:  2022-10-18       Impact factor: 17.694

4.  Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma.

Authors:  Haruhiko Yamazaki; Hiroyuki Iwasaki; Nobuyasu Suganuma; Soji Toda; Katsuhiko Masudo; Hirotaka Nakayama; Yasushi Rino; Munetaka Masuda
Journal:  Gland Surg       Date:  2021-03

5.  Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.

Authors:  Chunyan Zhou; Dong Duan; Shuang Liu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

6.  The prognostic value of the lymphocyte-to-monocyte ratio for high-risk papillary thyroid carcinoma.

Authors:  Linlin Song; Jingqiang Zhu; Zhihui Li; Tao Wei; Rixiang Gong; Jianyong Lei
Journal:  Cancer Manag Res       Date:  2019-09-17       Impact factor: 3.989

7.  Adaptor protein LNK promotes anaplastic thyroid carcinoma cell growth via 14-3-3 ε/γ binding.

Authors:  Zhao-Ming Zhong; Xue Chen; Xiao Qi; Xue-Min Wang; Chun-Yan Li; Ru-Jia Qin; Shi-Qi Wang; Jin Liang; Mu-Sheng Zeng; Chuan-Zheng Sun
Journal:  Cancer Cell Int       Date:  2020-01-09       Impact factor: 5.722

8.  Prognostic Value of the Neutrophil-to-Lymphocyte Ratio before and after Radiotherapy for Anaplastic Thyroid Carcinoma.

Authors:  Jiyun Park; Jun Park; Jung-Hee Shin; Young-Lyun Oh; Hyun-Ae Jung; Man-Ki Chung; Jun-Ho Choe; Yong-Chan Ahn; Sun-Wook Kim; Jae-Hoon Chung; Tae-Hyuk Kim; Jae-Myoung Noh
Journal:  Cancers (Basel)       Date:  2021-04-15       Impact factor: 6.639

9.  Association of the Preoperative Inflammation-Based Scores with TNM Stage and Recurrence in Patients with Papillary Thyroid Carcinoma: A Retrospective, Multicenter Analysis.

Authors:  Wenjie Chen; Tao Wei; Zhihui Li; Rixiang Gong; Jianyong Lei; Jingqiang Zhu; Tao Huang
Journal:  Cancer Manag Res       Date:  2020-03-11       Impact factor: 3.989

Review 10.  Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer.

Authors:  Won Bae Kim; Min Ji Jeon; Won Gu Kim; Tae Yong Kim; Young Kee Shong
Journal:  Endocrinol Metab (Seoul)       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.